Morgan Stanley cites supply issues for Mounjaro slowdown in Brazil By Investing.com

Morgan Stanley says the recent slowdown in Mounjaro sales is likely due to supply constraints rather than weaker demand, citing consistently limited retail availability and weak U.S. GLP-1 imports in December and January followed by a sharp rebound in February that could mark a near-term inflection in IQVIA data. The firm notes improving import trends ease immediate concerns for Raia Drogasil but requires IQVIA confirmation to de-risk sales momentum. Semaglutide faces structural challenges as patients shift to Mounjaro and pressure is expected to increase after loss of exclusivity; pricing remains broadly stable with only early, selective Mounjaro discounts and no clear evidence of Novo Nordisk’s announced portfolio-wide price cuts.

Analysis

If the recent revenue noise is supply-driven rather than demand-driven, expect a near-term catch-up in reported volumes as channels restock; that creates a 2–8 week window where service providers and pharmacies print outsized sequential growth but may face a follow-on inventory digestion phase that compresses growth in months 2–4. IQVIA-type data vendors and CROs have asymmetric upside in that scenario because their revenue and bookings flow from utilization and study activity that reaccelerates quickly, whereas incumbent manufacturers face margin lag (manufacturing lead times + contract cadence) before sales normalize.

Competitive dynamics are changing structurally: a fast-growing entrant that pulls share from an incumbent creates two offsetting P&L effects — payer resistance and downstream formulary engineering that can blunt price realization within 6–18 months, and faster conversion of market share that erodes the incumbent’s utilization base. Second-order winners include specialty distributors, analytics vendors, and outsourced manufacturing (CMOs) who capture the restocking and scale-up demand spike; losers are incumbents with single-product concentration and exposed margin profiles as biosimilar/alternative pathways open up post-exclusivity.

Key catalysts and risks are well-delineated by cadence. Watch weekly/monthly channel and import statistics for a technical inflection in 2–6 weeks, and watch payer messaging/coverage changes and patent expiration milestones on a 6–24 month horizon for structural profit impact. Tail risks that would reverse the supply-led rebound include a safety/label event, sudden API export restrictions, or a rapid payer prescribing clampdown — any of which would flip the trade from transient restock upside to durable volume impairment within weeks.

Key Decisions for Investors

• Long IQV (6–12 week tactical): Buy IQV with a 2–3% portfolio allocation to play the restock/data-rebound trade; set a tactical target of +25–35% (or ~15–20% absolute) and a stop loss at -8–10%. Rationale: weekly channel data should re-rate a services/data vendor sooner than manufacturers recover revenue recognition.
• Pair trade — Long IQV / Short NVO (3–12 month): Size 1.0x long IQV vs 0.6x short NVO to reflect relative balance-sheet liquidity. Target a 20–30% relative outperformance over 3–12 months driven by IQV’s operational leverage to utilization and NVO’s margin risk from substitution and post-exclusivity pricing pressure; stop if the spread tightens by 10%.
• NVO options hedge (9–15 month): Buy a put spread to limit cost — e.g., buy a 30% OTM 12-month put and sell a 15% OTM 12-month put (adjust strikes to current spot). This caps downside cost while delivering 2–4x payoff if NVO suffers a >25–30% drawdown tied to pricing erosion or formulary losses.
• Event-watch cash allocation (2–8 weeks): Keep 1–2% cash to add on either (a) confirmed sequential channel/import prints that validate restock (add to IQV exposure) or (b) evidence of accelerating discounting/coverage restrictions (add to NVO hedge). Use investors’ alerts around weekly IQVIA prints and payer announcements as explicit execution triggers.